EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases

Anna Sheahan, Suzanne Anjohrin, Robert Suruki, Jeffrey L Stark, Victor S Sloan

Clinical Rheumatology · 2024

DOI: 10.1007/s10067-024-06945-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Anna Sheahan und 4 weiteren Autor:innen. Beteiligte Einrichtung: UCB Pharma, Smyrna, GA, USA. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Arthritis, Rheumatoid, Analgesics, Opioid, Arthritis, Psoriatic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe patients’ use of opioids in the year preceding and year following new diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), compared with patients without the/se diseases.

Methods

This study used US IBM ® MarketScan ® Commercial Claims and Encounters (CCAE) and Medicaid data and included three cohorts, comprised of incident cases of AS, PsA, or RA (2010–2017). Three matched comparator patients (without the incident disease) were selected for each patient within the disease cohort. Opioid use and appropriate treatment exposure (as defined by US guideline recommendations) in the 12-month baseline and follow-up periods were evaluated using descriptive analyses.

Results

Prevalence of claims for opioids was higher for disease cohorts vs. comparators in CCAE; 36.4% of patients with AS, 29.5% with PsA, and 44.4% with RA did not have any claim for guideline-appropriate therapy in follow-up. Prevalence of claims for opioids was also higher for disease cohorts vs. comparators in Medicaid; 30.6% of patients with AS, 36.6% with PsA, and 65.4% with RA did not have any claim for guideline-appropriate therapy in follow-up.

Conclusions

In patients with AS, PsA, or RA, there was high reliance on opioids at and around the time of diagnosis. Significant proportions of patients were not on appropriate treatment as defined by professional society post-diagnosis guidelines; this discordance between actual patient therapies and treatment recommendations may suggest a need for better awareness of appropriate pain management and treatment strategies in rheumatic diseases. Key Points • This study analysed opioid use among patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), and adds to current knowledge by expanding beyond assessment of opioid use at diagnosis, to the year before and after diagnosis .• Opioid use was found to be highly prevalent in AS, PsA, and RA in the year prior to diagnosis and, interestingly, was still seen during the year after diagnosis .• Opioids are neither disease modifying, nor a targeted/recommended treatment for chronic autoimmune diseases. In addition to their association with significant economic costs, opioids are potentially hazardous and are not better than alternative treatments with superior safety profiles .• The reasons behind opioid prescribing patterns should be explored further to support movement to targeted therapies .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingArthritis, RheumatoidAnalgesics, OpioidArthritis, PsoriaticHumansMiddle AgedMaleFemaleAdultUnited StatesDatabases, FactualAgedPrevalenceFollow-Up StudiesMedicaidYoung Adult

Stichwörter der Autor:innen

Ankylosing spondylitisMedicaidOpioidsPain managementPsoriatic arthritisRheumatoid arthritis

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • UCB Pharma, Smyrna, GA, USA.
  • UCB Pharma, Smyrna, GA, USA. jeffrey.stark@ucb.com.
  • Sheng Consulting LLC, Flemington, NJ, USA.

Förderung

  • UCB Pharma

Zitieren

APA

Sheahan, A., Anjohrin, S., Suruki, R., Stark, J. L., & Sloan, V. S. (2024). Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-06945-0

Vancouver

Sheahan A, Anjohrin S, Suruki R, Stark JL, Sloan VS. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-06945-0

BibTeX
@article{Sheahan2024,
  author = {Sheahan, Anna and Anjohrin, Suzanne and Suruki, Robert and Stark, Jeffrey L and Sloan, Victor S},
  title = {Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases},
  journal = {Clinical Rheumatology},
  year = {2024},
  doi = {10.1007/s10067-024-06945-0}
}
Kostenlos starten →